scorecardresearch
Add as a preferred source on Google
Saturday, April 4, 2026
TopicCovaxin

Topic: Covaxin

Panel formed by Siddaramaiah finds no link between COVID-19 vaccines & Hassan cardiac-related deaths

Expert team, headed by Jayadeva Institute of Cardiovascular Sciences & Research head, has instead said that vaccine has shown to be ‘protective’ against cardiac events.

After filing for Covaxin patent solo, Bharat Biotech to add ICMR as co-inventor

Hyderabad-based vaccine maker says not including ICMR in original patent application for Covaxin was ‘inadvertent error’ & ‘confidential agreement between them was not accessible’.

ICMR seeks retraction of BHU study linking high rate of adverse health events with Covaxin

Study, which said nearly 30 percent of Covaxin recipients suffered from one or other side-effects, is 'misleading', says ICMR head. Journal & authors threatened with legal action.

‘Fake news’ — Bharat Biotech, govt deny report on ‘discrepancies’ in Covaxin trial data

Medical news site STAT had cited internal documents to allege that Bharat Biotech had taken ‘questionable’ steps under political pressure to speed up development of Covaxin.

Covaxin safe for kids, generates higher antibody response in them than adults, says Lancet paper

The results of the phase ⅔ clinical trials of the indigenous Covid vaccine have been peer-reviewed and published in the The Lancet Infectious Diseases journal.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

As booster uptake lags in pvt sector, officials say health system can’t be in Covid mode forever

Third Covid vaccine dose available only in pvt hospitals. Health officials say routine procedures need to be brought back on track, but govt hospitals could be brought in if needed.

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

Covaxin supplies, trial group size — why there’s a delay in Covid vaccine for younger kids

Monthly Covaxin output between 5.5-6.5 cr. Country needs at least 15 cr doses for full coverage 15-18 age group. Choice of 6 μg dose reduced manufacturing capacity, says Bharat Biotech.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

On Camera

The influencer war that took rural creator Pujarini Pradhan global

As social media debated whether audiences were consuming Pujarini Pradhan as a symbol, The Juggernaut turned her into a story that could circulate globally, with or without her participation.

SEBI proposes return of open market share buybacks to support stocks

Regulator seeks feedback on allowing firms to repurchase shares via exchanges after tax changes, as markets reel from war-led selloff and foreign outflows.

South Korea’s Cheongung-II missile system makes its mark in West Asia war. Here’s why

UAE has been using this defence system, which is similar to America's Patriots, against Iranian missiles and unmanned aerial vehicles.

China insulated itself against energy shocks. India is ‘all talk, no walk’

China patiently invested capital, skill and technology in coal gasification. Unlike it, we won’t move from words to action. As crude prices decline, we lose interest.